Related Experiment Video
Updated: May 12, 2026

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
Published on: April 15, 2016
Nivolumab-Associated Acute Liver Failure: A Report of Two Cases
Lekshmi R Shenoi1, Saquib Z Banday1, Kalpana Acharya2
1Medical Oncology, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, IND.
None:
Nivolumab is utilized for treating multiple advanced malignancies, with a fraction of patients experiencing immune-related side effects due to immune enhancement. Severe immune-related hepatic injury from nivolumab is very rare and typically responds well to corticosteroids. Here, we present two cases illustrating this phenomenon: one involving extensive-stage small cell carcinoma of the lung with disseminated liver and bone metastasis where nivolumab was administered as a fourth-line treatment and another involving uveal melanoma with liver metastasis where nivolumab was given as first-line palliative systemic therapy. Both cases demonstrated accelerated hepatic deterioration and unresponsiveness to timely steroid administration following the first cycle of nivolumab administration in 3-11 days.
Related Concept Videos
Drug Toxicity: Risk factors
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Acute Kidney Injury III: Clinical Manifestations
Drug Toxicity: Overview
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Acute Kidney Injury I: Introduction
